Close
Citizen’s Charter
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Menu
Citizen’s Charter
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Search
Home
About FDA
Transparency
Issuances
Advisories
Advisories
Lifting Advisories
Old FDA Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Philippine National Standards
Old Issuances
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
Menu
Home
About FDA
Transparency
Issuances
Advisories
Advisories
Lifting Advisories
Old FDA Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Philippine National Standards
Old Issuances
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
Newsletters and Bulletins
Pharmacovigilance
Information for the patients
Information for doctors, nurses, and pharmacists
Information for pharmaceutical industry
COVID-19 vaccines information
Newsletters and bulletins
Annual Report
PV Educational Materials
Forms
Glossary
FAQs
Drug Safety Newsletter
2024
Volume 2 Issue 1
2023
Volume 1 Issue 1
Safety Information
2024
Topical corticosteroids and increased risk of misuse and abuse
Domperidone and increased risk of serious ventricular arrhythmia
Bupivacaine and reports of failed or incomplete spinal anesthesia
2023
Pholcodine and pholcodine-containing drug products and risk of anaphylactic reactions
2019
Incorrect use of anti-fungal corticosteroid combination therapy
Unsafe use of glutathione as skin lightening agent
SGLT2 inhibitors and risk of necrotizing fasciitis of the perineum (Fournier’s gangrene)
Fluoroquinolones and risk of aortic aneurysm and dissection
Last updated: 29 February 2024
Shares